3 results
Not approvedWill not start
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
Approved WMOCompleted
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
Approved WMOPending
Primary objective:The main objective of the present trial are:• to evaluate the effect of TW001 on oxidative stress biomarkers• to evaluate the safety of TW001 in patients with Alzheimer*s DiseaseSecondary objective:The secondary objective of the…